[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Stock Sinks As Market Gains: Here's Why",
    "summary": "Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=fcfa583831201ee81485fea1c58e8da8cae03ecb9e2f3ad2d29e9bb05958ec53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752529502,
      "headline": "Pfizer (PFE) Stock Sinks As Market Gains: Here's Why",
      "id": 135937094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=fcfa583831201ee81485fea1c58e8da8cae03ecb9e2f3ad2d29e9bb05958ec53"
    }
  },
  {
    "ts": null,
    "headline": "Building A $100,000 Dividend Portfolio: Maximizing SCHD's Income With July's Top High-Yield Stocks",
    "summary": "SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend growth potential. See more here.",
    "url": "https://finnhub.io/api/news?id=62111ff39abfd05d68d3375b8580d015752f8dfee556c62d124dce3105ba7bfb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752516000,
      "headline": "Building A $100,000 Dividend Portfolio: Maximizing SCHD's Income With July's Top High-Yield Stocks",
      "id": 135931105,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209908358/image_2209908358.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend growth potential. See more here.",
      "url": "https://finnhub.io/api/news?id=62111ff39abfd05d68d3375b8580d015752f8dfee556c62d124dce3105ba7bfb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock underperforms Monday when compared to competitors",
    "summary": "Pfizer Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=212de1f3d163a4ef09dd848983674cbe1f26e2ab35c5a5a12a1afb9378940482",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752510960,
      "headline": "Pfizer Inc. stock underperforms Monday when compared to competitors",
      "id": 135950838,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=212de1f3d163a4ef09dd848983674cbe1f26e2ab35c5a5a12a1afb9378940482"
    }
  },
  {
    "ts": null,
    "headline": "FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults",
    "summary": "FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.",
    "url": "https://finnhub.io/api/news?id=0b28c245c37994714e1bc6d07a76677aea276d00e47ba6c90b00cf0910762d74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752502320,
      "headline": "FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults",
      "id": 135929797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.",
      "url": "https://finnhub.io/api/news?id=0b28c245c37994714e1bc6d07a76677aea276d00e47ba6c90b00cf0910762d74"
    }
  },
  {
    "ts": null,
    "headline": "ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment",
    "summary": "LONDON, July 14, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced an update to their voluntary licensing agreement with the Medicines Patent Pool (MPP) for cabotegravir to include patents relating to its use in a long-acting HIV treatment regimen. The announcement follows updated guidance from WHO recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option.",
    "url": "https://finnhub.io/api/news?id=9ec24aed9b56531a18540270aaa9f8c897d8f0451c8d0ac5443681c7e706d07a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752499680,
      "headline": "ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment",
      "id": 135927725,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LONDON, July 14, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced an update to their voluntary licensing agreement with the Medicines Patent Pool (MPP) for cabotegravir to include patents relating to its use in a long-acting HIV treatment regimen. The announcement follows updated guidance from WHO recommending long-acting injectable cabotegravir + rilpivirine as an HIV treatment option.",
      "url": "https://finnhub.io/api/news?id=9ec24aed9b56531a18540270aaa9f8c897d8f0451c8d0ac5443681c7e706d07a"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know",
    "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=3969a9ca8033f4898e5f08bc4675d3f4b69547c1e91f2c9f3dde2cdacf4ef966",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752498003,
      "headline": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know",
      "id": 135927726,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=3969a9ca8033f4898e5f08bc4675d3f4b69547c1e91f2c9f3dde2cdacf4ef966"
    }
  },
  {
    "ts": null,
    "headline": "AnaptysBio: Potential Promise, But Some Cause For Skepticism",
    "summary": "AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.",
    "url": "https://finnhub.io/api/news?id=a8f2a499ca9319c5d73cf6d5524bcd8a35a420e9b32cb33fb26f779c2f4e0f05",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752490011,
      "headline": "AnaptysBio: Potential Promise, But Some Cause For Skepticism",
      "id": 135926879,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192786673/image_2192786673.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.",
      "url": "https://finnhub.io/api/news?id=a8f2a499ca9319c5d73cf6d5524bcd8a35a420e9b32cb33fb26f779c2f4e0f05"
    }
  },
  {
    "ts": null,
    "headline": "Obesity Drug Pipeline Analysis Report 2025 | Pfizer and Eli Lilly Lead the Charge in Cutting-Edge Obesity Research",
    "summary": "In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical support bolstering development. The 2025 Obesity Drug Pipeline Report offers insights into recent breakthroughs, clinical trials, and regulatory trends, highlighting the shift toward personalized therapies and novel drug classes like peptides and RNA-based treatments. Key players include Pfizer and Eli L",
    "url": "https://finnhub.io/api/news?id=bf831dc0f077513f8d51e1e3b36151a67ad12aa03ca98defb9b11525ad47eca5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752486360,
      "headline": "Obesity Drug Pipeline Analysis Report 2025 | Pfizer and Eli Lilly Lead the Charge in Cutting-Edge Obesity Research",
      "id": 135920859,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical support bolstering development. The 2025 Obesity Drug Pipeline Report offers insights into recent breakthroughs, clinical trials, and regulatory trends, highlighting the shift toward personalized therapies and novel drug classes like peptides and RNA-based treatments. Key players include Pfizer and Eli L",
      "url": "https://finnhub.io/api/news?id=bf831dc0f077513f8d51e1e3b36151a67ad12aa03ca98defb9b11525ad47eca5"
    }
  },
  {
    "ts": null,
    "headline": "GSK seeks FDA nod for expanded use of RSV vaccine in adults",
    "summary": "If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo.  RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults.  GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59.",
    "url": "https://finnhub.io/api/news?id=a1126203e4029088cdfb663cf66ee0afb37a9cd23f7d9a9f413593759e0047cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752475328,
      "headline": "GSK seeks FDA nod for expanded use of RSV vaccine in adults",
      "id": 135920860,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo.  RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults.  GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59.",
      "url": "https://finnhub.io/api/news?id=a1126203e4029088cdfb663cf66ee0afb37a9cd23f7d9a9f413593759e0047cd"
    }
  }
]